Theodore Tzeremas, MD
Nephrology · Tempe, AZNPI 1831252469
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,363, 4.6 times the $295 reported in 2019.
Across 279 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$747
- Bayer$595
- Amgen$451
- Otsuka America Pharmaceutical, Inc.$363
- Mallinckrodt Hospital Products Inc.$355
- Boehringer Ingelheim$343
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,39094%
- Education$3196%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 38 | $747 |
| Bayer | 37 | $595 |
| Amgen(2 entities) | 23 | $451 |
| Otsuka America Pharmaceutical, Inc. | 18 | $363 |
| Mallinckrodt Hospital Products Inc. | 12 | $355 |
| Boehringer Ingelheim | 18 | $343 |
| GSK | 19 | $321 |
| ANI Pharmaceuticals, Inc. | 14 | $299 |
| Calliditas Therapeutics US Inc. | 8 | $260 |
| Akebia Therapeutics Inc | 11 | $224 |
| Daiichi Sankyo Inc. | 11 | $217 |
| Vifor Pharma, Inc. | 10 | $215 |
| Travere Therapeutics, Inc. | 10 | $213 |
| OPKO Pharmaceuticals, LLC | 11 | $184 |
| Vantive US Healthcare LLC | 1 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $104 |
| Aurinia Pharma U.S., Inc. | 5 | $99 |
| Novartis | 4 | $84 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $81 |
| Mallinckrodt Enterprises LLC | 4 | $78 |
| Xeris Pharmaceuticals, Inc. | 4 | $69 |
| Lilly USA, LLC | 2 | $42 |
| Boston Scientific | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Abbott | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Cvrx, Inc. | 1 | $22 |
| Ardelyx, Inc. | 1 | $22 |
| Renalytix AI, Inc. | 1 | $19 |
| Sanofi | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| Cormedix Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$108
How this compares
$5,709 in reported general payments places this provider in the 80th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 98 | $283,311 |
| FarxigaDapagliflozin Propanediol | 177 | $170,059 |
| JardianceEmpagliflozin | 84 | $80,494 |
| KerendiaFinerenone | 53 | $64,222 |
| AuryxiaFerric Citrate | 11 | $23,853 |
| Sevelamer Carbonate | 84 | $21,862 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $17,093 |
| EntrestoSacubitril/Valsartan | 12 | $10,777 |
| Calcium Acetate | 49 | $7,015 |
| Cinacalcet Hcl | 28 | $6,532 |
| Bumetanide | 92 | $4,017 |
| Nifedipine ErNifedipine | 142 | $3,981 |
| ProsolParenteral Amino Acid 20% No.1 | 41 | $3,979 |
| Losartan Potassium | 344 | $3,721 |
| Allopurinol | 360 | $3,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $747 | $187,152197 claims |
| Boehringer IngelheimJardiance | $343 | $80,49484 claims |
| BayerKerendia | $595 | $64,22253 claims |
| Akebia Therapeutics IncAuryxia | $224 | $23,85311 claims |
| NovartisEntresto | $84 | $10,77712 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $299 | $35317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 259 nephrology providers in Arizona.
Other nephrology in Tempe
- Shailesh PatelTempe$10K
- Rajan KapoorTempe$6K
- Clyde MendoncaTempe$5K
- Randy CooperPeoria$597K
- Minesh RajpalPeoria$403K
- Umar WaheedPeoria$150K
- Amer KhanPeoria$71K
- Samer Bani HaniPhoenix$54K
- Aneesha ShettyTucson$34K
- Leslie ThomasPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.